Pfizer's Braftovi Significantly Extends Survival in Advanced Colorectal Cancer
TL;DR Summary
A late-stage trial found that a Pfizer combination therapy, including chemotherapy, cetuximab, and Braftovi, doubled survival time for patients with aggressive colorectal cancer with BRAF V600E mutation, setting a new standard of care for this subset of patients.
- Advanced colon cancer patients lived twice as long with a Pfizer combo therapy, trial finds NBC News
- ASCO25: Pfizer's Braftovi confers 'unprecedented' survival benefit in CRC FirstWord Pharma
- Pfizer’s Braftovi Doubles Survival in Advanced Colorectal Cancer Bloomberg.com
- Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer Yahoo Finance
- ASCO: Pfizer, chasing full approval conversion for Braftovi combo, touts 'unprecedented' survival win Fierce Pharma
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
95%
720 → 38 words
Want the full story? Read the original article
Read on NBC News